TN2017000280A1 - NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT - Google Patents

NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Info

Publication number
TN2017000280A1
TN2017000280A1 TNP/2017/000280A TN2017000280A TN2017000280A1 TN 2017000280 A1 TN2017000280 A1 TN 2017000280A1 TN 2017000280 A TN2017000280 A TN 2017000280A TN 2017000280 A1 TN2017000280 A1 TN 2017000280A1
Authority
TN
Tunisia
Prior art keywords
oxazino
benzotriazine
antidepressant
dione
fluorophenyl
Prior art date
Application number
TNP/2017/000280A
Other languages
French (fr)
Inventor
Sylvie Bretin
Laurence Danober
Pierre Lestage
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of TN2017000280A1 publication Critical patent/TN2017000280A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

.Association entre le 8-cyclopropyl-3-[2-(3-fluorophényl)éthyl]-7,8-dihydro-3H- [1,3]oxazino[6,5-g] [l,2,3]benzotriazine-4,9-dione de formule (I): ou un de ses sels d'addition à un acide ou à une base pharmaceutiquement acceptable, et un antidépresseur.  Médicaments.Association between 8-cyclopropyl-3- [2- (3-fluorophenyl) ethyl] -7,8-dihydro-3H- [1,3] oxazino [6,5-g] [1,2,3] benzotriazine -4,9-dione of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, and an antidepressant. Drugs.

TNP/2017/000280A 2015-03-26 2016-03-25 NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT TN2017000280A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1552563A FR3034019B1 (en) 2015-03-26 2015-03-26 NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-G] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
PCT/FR2016/050681 WO2016151265A1 (en) 2015-03-26 2016-03-25 Novel combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione with an antidepressant, and the pharmaceutical compositions containing same

Publications (1)

Publication Number Publication Date
TN2017000280A1 true TN2017000280A1 (en) 2019-01-16

Family

ID=53776719

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2017/000280A TN2017000280A1 (en) 2015-03-26 2016-03-25 NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Country Status (12)

Country Link
EP (1) EP3273996A1 (en)
JP (1) JP2018509436A (en)
KR (1) KR20170125835A (en)
AU (1) AU2016238625A1 (en)
CA (1) CA2975571A1 (en)
FR (1) FR3034019B1 (en)
MA (1) MA41817A (en)
PH (1) PH12017501248A1 (en)
SG (1) SG11201706076QA (en)
TN (1) TN2017000280A1 (en)
WO (1) WO2016151265A1 (en)
ZA (1) ZA201705052B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2144506T3 (en) * 2007-01-03 2012-04-30 Servier Lab 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
PH12017501248A1 (en) 2017-10-30
MA41817A (en) 2018-01-30
WO2016151265A1 (en) 2016-09-29
JP2018509436A (en) 2018-04-05
ZA201705052B (en) 2019-02-27
FR3034019B1 (en) 2017-03-17
AU2016238625A1 (en) 2017-08-03
CA2975571A1 (en) 2016-09-29
EP3273996A1 (en) 2018-01-31
SG11201706076QA (en) 2017-08-30
FR3034019A1 (en) 2016-09-30
KR20170125835A (en) 2017-11-15

Similar Documents

Publication Publication Date Title
EP4292650A3 (en) Heterocyclic compounds as immunomodulators
CO2018011064A2 (en) Bromodomain Inhibitors
MA41265B1 (en) Compositions for administration of ileo-jejunal drugs.
EA201791019A1 (en) POLYCYCLIC CARBAMOILPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATIONS
UY36056A (en) "FUSIONED BICYCLIC HETEROARILO OR ARILO COMPOUNDS".
FR3037957B1 (en) NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
MX2017012393A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
FR3037958B1 (en) NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR112012027743A2 (en) cyclopropyl dicarboxamides and analogs exhibiting anticancer and antiproliferative activities
EA201992116A1 (en) PHARMACEUTICAL COMPOSITIONS OF FLOROGLUCINOL AND TRIMETHYLFLOROGLUCINOL
MX2019014292A (en) 5-5 FUSED RINGS AS C5a INHIBITORS.
SA518390920B1 (en) Novel annelated phenoxyacetamides
EA201890532A1 (en) NEW ANNELED BENZAMIDES
MA43876A (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USES AGAINST LYSOSOMAL OVERLOAD DISEASES
TR201819805T4 (en) FLAVAGLIN DERIVATIVES.
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MA39448B1 (en) (r) -pirlindole and its pharmaceutically acceptable salts for medical use
EA201990668A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ANTAGONIST OF MINERALOCORTICOID RECEPTORS AND ITS APPLICATION
EA201500669A1 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION CONTAINING REGORAPHENIB
MA39450A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
TN2017000280A1 (en) NOVEL ASSOCIATION BETWEEN 8-CYCLOPROPYL-3- [2- (3-FLUOROPHENYL) ETHYL] -7,8-DIHYDRO-3H- [1,3] OXAZINO [6,5-g] [1,2,3] BENZOTRIAZINE -4,9-DIONE AND AN ANTIDEPRESSANT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EA201892583A1 (en) COMBINATION OF PURE ANTAGONISTS OF A 5-HT RECEPTOR WITH AN ANTAGONIST OF NMDA RECEPTOR
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
MX2020009711A (en) Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination.